Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-γ production of CD8+ T cells in secondary progressive multiple sclerosis

This publication has 38 references indexed in Scilit:

• Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1
  Proceedings of the National Academy of Sciences, 2000
• CCR5⁺and CXCR3⁺T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions
  Proceedings of the National Academy of Sciences, 1999
• Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy.
  Journal of Clinical Investigation, 1998
• Differential Expression of Chemokine Receptors and Chemotactic Responsiveness of Type 1 T Helper Cells (Th1s) and Th2s
  The Journal of Experimental Medicine, 1998
• Mechanisms of interferon beta action in multiple sclerosis
  Multiple Sclerosis Journal, 1997
• Interferon beta results in immediate reduction of contrast‐enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI
  Neurology, 1997
• Human Chemokines: An Update
  Annual Review of Immunology, 1997
• Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b
  Neurology, 1995
• Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: Do cytokines trigger off exacerbations?
  Acta Neurologica Scandinavica, 1988
• The effect of cyclophosphamide on T lymphocytes and T lymphocyte subsets in patients with chronic progressive multiple sclerosis
  Acta Neurologica Scandinavica, 1984